Early‐onset reduced bone mineral density in patients with pyruvate kinase deficiency
Hanny Al‐Samkari(Harvard University), Eduard J. van Beers(Utrecht University), Wilma Barcellini(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), John B. Porter(Royal London Hospital), Jaime Morales‐Arias(Agios Pharmaceuticals (United States)), Oliver Andrés(University of Würzburg), Kevin H.M. Kuo(University Health Network), Keely Gilroy(Agios Pharmaceuticals (United States)), Sarah Gheuens(Biogen (United States)), Frederic Galactéros(Inserm), Peter Hawkins(Agios Pharmaceuticals (United States)), Vip Viprakasit(Siriraj Hospital), Yan Dong(Agios Pharmaceuticals (United States)), Andreas Glenthøj(University of Copenhagen), Feng Tai(Agios Pharmaceuticals (United States)), Marta Morado Arias(Hospital Universitario La Paz), D. Mark Layton(Imperial College Healthcare NHS Trust), Rachael F. Grace(Dana-Farber/Boston Children's Cancer and Blood Disorders Center)
Cited by 4
Related Papers
Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study
|Neuromuscular Disorders|2019|636
Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients
|Blood|2014|373
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia
|New England Journal of Medicine|2020|320
Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia
|New England Journal of Medicine|2022|309